BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

80 related articles for article (PubMed ID: 23644213)

  • 1. Low molecular weight dual inhibitors of factor Xa and fibrinogen binding to GPIIb/IIIa with highly overlapped pharmacophores.
    Trstenjak U; Ilaš J; Kikelj D
    Eur J Med Chem; 2013 Jun; 64():302-13. PubMed ID: 23644213
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The anti-platelet approach targeting the fibrinogen ligand of the GPIIB/IIIa receptor.
    Tsikaris V
    J Pept Sci; 2004 Oct; 10(10):589-602. PubMed ID: 15526708
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Synthesis and structure-activity relationship of potent, selective and orally active anthranilamide-based factor Xa inhibitors: application of weakly basic sulfoximine group as novel S4 binding element.
    Pandya V; Jain M; Chakrabarti G; Soni H; Parmar B; Chaugule B; Patel J; Jarag T; Joshi J; Joshi N; Rath A; Unadkat V; Sharma B; Ajani H; Kumar J; Sairam KV; Patel H; Patel P
    Eur J Med Chem; 2012 Dec; 58():136-52. PubMed ID: 23124211
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Towards dual antithrombotic compounds - balancing thrombin inhibitory and fibrinogen GPIIb/IIIa binding inhibitory activities of 2,3-dihydro-1,4-benzodioxine derivatives through regio- and stereoisomerism.
    Ilić M; Dunkel P; Ilaš J; Chabielska E; Zakrzeska A; Mátyus P; Kikelj D
    Eur J Med Chem; 2013 Apr; 62():329-40. PubMed ID: 23376251
    [TBL] [Abstract][Full Text] [Related]  

  • 5. 3,4-Dihydro-2H-1,4-benzoxazine derivatives combining thrombin inhibitory and glycoprotein IIb/IIIa receptor antagonistic activity as a novel class of antithrombotic compounds with dual function.
    Ilas J; Jakopin Z; Borstnar T; Stegnar M; Kikelj D
    J Med Chem; 2008 Sep; 51(18):5617-29. PubMed ID: 18729445
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Design, synthesis and SAR of novel ethylenediamine and phenylenediamine derivatives as factor Xa inhibitors.
    Yoshikawa K; Yoshino T; Yokomizo Y; Uoto K; Naito H; Kawakami K; Mochizuki A; Nagata T; Suzuki M; Kanno H; Takemura M; Ohta T
    Bioorg Med Chem Lett; 2011 Apr; 21(7):2133-40. PubMed ID: 21345673
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inhibition of fibrinogen binding and surface recruitment of GpIIb/IIIa as dose-dependent effects of the RGD-mimetic MK-852.
    Wittig K; Rothe G; Schmitz G
    Thromb Haemost; 1998 Mar; 79(3):625-30. PubMed ID: 9531053
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Toward a novel class of antithrombotic compounds with dual function. Discovery of 1,4-benzoxazin-3(4H)-one derivatives possessing thrombin inhibitory and fibrinogen receptor antagonistic activities.
    Stefanic Anderluh P; Anderluh M; Ilas J; Mravljak J; Sollner Dolenc M; Stegnar M; Kikelj D
    J Med Chem; 2005 May; 48(9):3110-3. PubMed ID: 15857114
    [TBL] [Abstract][Full Text] [Related]  

  • 9. 7-fluoroindazoles as potent and selective inhibitors of factor Xa.
    Lee YK; Parks DJ; Lu T; Thieu TV; Markotan T; Pan W; McComsey DF; Milkiewicz KL; Crysler CS; Ninan N; Abad MC; Giardino EC; Maryanoff BE; Damiano BP; Player MR
    J Med Chem; 2008 Jan; 51(2):282-97. PubMed ID: 18159923
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Profiling the structural determinants for the selectivity of representative factor-Xa and thrombin inhibitors using combined ligand-based and structure-based approaches.
    Bhunia SS; Roy KK; Saxena AK
    J Chem Inf Model; 2011 Aug; 51(8):1966-85. PubMed ID: 21761917
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Conformational changes of the platelet membrane glycoprotein IIb-IIIa complex stimulated by a monoclonal antibody to the N-terminal segment of glycoprotein IIIa].
    Khaspekova SG; Vyzova TV; Lukin VV; Tikhomirov OIu; Berndt M; Kouns W; Mazurov AV
    Biokhimiia; 1996 Mar; 61(3):412-28. PubMed ID: 8724599
    [TBL] [Abstract][Full Text] [Related]  

  • 12. GPIIb/IIIa inhibitors: from bench to bedside and back to bench again.
    Armstrong PC; Peter K
    Thromb Haemost; 2012 May; 107(5):808-14. PubMed ID: 22370973
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Novel factor Xa inhibitors based on a 2-carboxyindole scaffold: SAR of P4 substituents in combination with a neutral P1 ligand.
    Nazaré M; Essrich M; Will DW; Matter H; Ritter K; Urmann M; Bauer A; Schreuder H; Czech J; Lorenz M; Laux V; Wehner V
    Bioorg Med Chem Lett; 2004 Aug; 14(16):4197-201. PubMed ID: 15261269
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The antithrombotic activity of EP224283, a neutralizable dual factor Xa inhibitor/glycoprotein IIbIIIa antagonist, exceeds that of the coadministered parent compounds.
    Hechler B; Freund M; Alame G; Leguay C; Gaertner S; Cazenave JP; Petitou M; Gachet C
    J Pharmacol Exp Ther; 2011 Aug; 338(2):412-20. PubMed ID: 21527535
    [TBL] [Abstract][Full Text] [Related]  

  • 15. New platelet fibrinogen receptor glycoprotein IIb-IIIa antagonists: orally active series of N-alkylated amidines with a 6,6-bicyclic template.
    Okumura K; Shimazaki T; Aoki Y; Yamashita H; Tanaka E; Banba S; Yazawa K; Kibayashi K; Banno H
    J Med Chem; 1998 Oct; 41(21):4036-52. PubMed ID: 9767641
    [TBL] [Abstract][Full Text] [Related]  

  • 16. New orally active non-peptide fibrinogen receptor (GpIIb-IIIa) antagonists: identification of ethyl 3-[N-[4-[4-[amino[(ethoxycarbonyl) imino]methyl]phenyl]-1,3-thiazol-2-yl]-N-[1-[(ethoxycarbonyl)methyl]pip erid -4-yl]amino]propionate (SR 121787) as a potent and long-acting antithrombotic agent.
    Badorc A; Bordes MF; de Cointet P; Savi P; Bernat A; Lalé A; Petitou M; Maffrand JP; Herbert JM
    J Med Chem; 1997 Oct; 40(21):3393-401. PubMed ID: 9341914
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The interaction of disagregin with the platelet fibrinogen receptor, glycoprotein IIb-IIIa.
    Karczewski J; Connolly TM
    Biochem Biophys Res Commun; 1997 Dec; 241(3):744-8. PubMed ID: 9434779
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The application of tetrahydroisoquinoline-3-carbonyl-TARGD(F)F as an anti-thrombotic agent having dual mechanisms of action.
    Yang G; Zhu H; Zhao M; Wu J; Wang Y; Wang Y; Zheng M; Chen M; Liu J; Peng S
    Mol Biosyst; 2012 Oct; 8(10):2672-9. PubMed ID: 22801714
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Rational design and synthesis of novel, potent bis-phenylamidine carboxylate factor Xa inhibitors.
    Maduskuie TP; McNamara KJ; Ru Y; Knabb RM; Stouten PF
    J Med Chem; 1998 Jan; 41(1):53-62. PubMed ID: 9438022
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Design, synthesis, and biological activity of potent and selective inhibitors of blood coagulation factor Xa.
    Willardsen JA; Dudley DA; Cody WL; Chi L; McClanahan TB; Mertz TE; Potoczak RE; Narasimhan LS; Holland DR; Rapundalo ST; Edmunds JJ
    J Med Chem; 2004 Jul; 47(16):4089-99. PubMed ID: 15267248
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.